Company intelligence / Profile preview

Zikorn Therapeutics

Watertown, Massachusetts, United Statesbiblio.com ↗

Ownership: Private
Development stage: Other

Overview

Zikani Therapeutics developed a proprietary TURBO-ZM™ chemistry platform to create novel small molecules called Ribosome Modulating Agents. These are designed to address rare genetic diseases and cancers driven by nonsense mutations. The company was acquired before advancing any program into late-stage clinical development. No published clinical results available.

Therapeutic areas: OncologyPulmonologyRare DiseasesGastroenterology
Modalities: Small moleculeRibosome Modulating Agent (RMA)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships disclosed prior to acquisition.

Beyond the preview

Go deeper on Zikorn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zikorn Therapeutics.

Explore the full profile